Dr Emma Beardsley, MBBS FRACP
Position:
- Clinical Fellow, Prostate Cancer Research Program, Monash University, Clayton, Melbourne, Vic, Australia
- Medical Oncologist, Department of Medicine, Peninsula Health - Frankston Hospital
- Medical Oncologist, Cabrini Brighton, Oncology Clinics Victoria
Credentials:
- Medical Oncologist at Monash University and The Royal Australasian College of Physicians (currently studying)
Biography:
Dr Beardsley completed a clinical fellowship (genitourinary and Prostate) and working as a medical oncologist at The British Columbia Cancer Agency, Vancouver, Canada. Upon returning to Australia, she commenced practice as a Medical Oncologist with special interest in Prostate and Genitourinary malignancies at both Public and Private Medical Facilities.
She is particularly interested in clinical trial work, which enables lab research to move forward into the clinical settling, provides patients with an opportunity to try medications otherwise unavailable to them, and provides clinicians with firsthand experience in managing these new agents.
Working with Prof Gail Risbridger and her team at Monash, her focus has been on xenografting Castrate Resistant Prostate Cancer. Her aim is to continue to bridge the gap between scientists and clinicians.
Dr Beardsley is particularly interested in improving the understanding of mechanisms involved in prostate cancer progression and targeting treatment towards these mechanisms, while minimising toxicity and maintaining quality of life in patients and their families affected by prostate cancer.
Best publications:
K.N. Chi, E. Beardsley, B. Eigl, P. Venner, S.J. Hotte, E. Winquist, Y.J. Ko, S. Sridhar, F. Saad.A phase 2 study of patupilone in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel. Annals of Oncology, In Press, 2011.
E.K. Beardsley, S.J. Hotte, S. Ellard, E. Winquist, S. North, K.N. Chi. A Phase II Study of Sorafenib in Combination with Bicalutamide in Patients with Chemotherapy-Naive Castration Resistant Prostate Cancer (CRPC). Investigational New Drugs, In Press, 2011
Beardsley, E.K. Chi, K.N. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2008 Sep;2(3):161-6.
Beardsley, E. Jefford, M. Mileshkin, L. Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening? J Clin Oncol. 2007 Mar 20;25(9):e13-4.
clinical research, translational science and drug development.
